Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Pegasys (pegylated interferon α -2a)
i
Other names:
RG 44, RG 964, RO253036, RO258310, RO25-8310, R-442, R-964, RG-44, RG-964, RO-253036, RO-258310, RO-25-8310, PEG IFN-alpha-2a, R442, R964, RG44, RG964, RO 253036, RO 25-8310, RO 258310, R 442, R 964
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Ascletis, Roche
Drug class:
IFNα stimulant
Related drugs:
‹
nadofaragene firadenovec-vncg (1)
interferon alfa 2b (0)
JZP898 (0)
NG-641 (0)
recombinant interferon alfa-2a (0)
SAR441000 (0)
Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)
peginterferon-α-2b (0)
IGN002 (0)
TAK-573 (0)
nadofaragene firadenovec-vncg (1)
interferon alfa 2b (0)
JZP898 (0)
NG-641 (0)
recombinant interferon alfa-2a (0)
SAR441000 (0)
Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)
peginterferon-α-2b (0)
IGN002 (0)
TAK-573 (0)
›
Associations
(3)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive: A1 - Approval
bevacizumab + pegylated interferon α -2a
Sensitive
:
A1
bevacizumab + pegylated interferon α -2a
Sensitive: A1 - Approval
bevacizumab + pegylated interferon α -2a
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive
:
A1
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive
:
A1
No biomarker
Clear Cell Renal Cell Carcinoma
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive: A2 - Guideline
bevacizumab + pegylated interferon α -2a
Sensitive
:
A2
bevacizumab + pegylated interferon α -2a
Sensitive: A2 - Guideline
bevacizumab + pegylated interferon α -2a
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login